Ascendis Pharma A/S (NASDAQ:ASND) Trading 4.4% Higher - Still a Buy?

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) rose 4.4% during mid-day trading on Friday . The stock traded as high as $160.97 and last traded at $167.52. Approximately 43,165 shares changed hands during mid-day trading, a decline of 91% from the average daily volume of 486,169 shares. The stock had previously closed at $160.45.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on ASND. JPMorgan Chase & Co. boosted their target price on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the company an "overweight" rating in a research note on Tuesday, March 18th. UBS Group assumed coverage on Ascendis Pharma A/S in a research note on Tuesday, January 7th. They set a "buy" rating and a $196.00 target price on the stock. The Goldman Sachs Group increased their price target on Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a research note on Thursday, February 13th. Morgan Stanley set a $180.00 price objective on shares of Ascendis Pharma A/S in a research note on Tuesday, February 18th. Finally, Evercore ISI increased their target price on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an "outperform" rating in a research report on Tuesday, February 18th. Two analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $204.67.

Ascendis Pharma A/S Stock Up 2.2 %

The business has a fifty day moving average of $153.64 and a 200 day moving average of $138.68. The firm has a market cap of $9.99 billion, a P/E ratio of -23.23 and a beta of 0.54.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, beating analysts' consensus estimates of ($1.32) by $0.64. On average, sell-side analysts expect that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Institutional Investors Weigh In On Ascendis Pharma A/S

A number of institutional investors and hedge funds have recently modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Ascendis Pharma A/S during the 4th quarter worth approximately $28,000. Wilmington Savings Fund Society FSB bought a new position in shares of Ascendis Pharma A/S in the third quarter valued at about $30,000. Jones Financial Companies Lllp lifted its stake in shares of Ascendis Pharma A/S by 394.0% during the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock worth $34,000 after buying an additional 197 shares during the last quarter. Blue Trust Inc. grew its stake in Ascendis Pharma A/S by 415.2% in the 4th quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock valued at $56,000 after buying an additional 328 shares during the last quarter. Finally, GAMMA Investing LLC raised its holdings in Ascendis Pharma A/S by 58.0% in the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock valued at $80,000 after acquiring an additional 214 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.